PARI’s Pipeline is focused primarily on projects in select markets where there appears to be little or no initial interest from pharmaceutical companies. As the first phase for these projects, PARI will work on commercialization in Europe. The data and IP generated in these European development projects present a potential pharmaceutical partnering or licensing opportunity in North America.

Currently we are utilizing eFlow Technology devices—unless otherwise specified in the graph below. We are preparing for future development with the Vibrent Technology platform that will concentrate on chronic sinusitis. New therapy development with Vibrent Technology will begin with specific patient groups, such as pre-sinus surgery patients.

[enlarge view]